Skip to main content

Table 3 Extent of mono- and combination drug therapy use in the male LUTS (including OAB) sub-cohort

From: The use of mono- and combination drug therapy in men and women with lower urinary tract symptoms (LUTS) in the UK: a retrospective observational study

Monotherapy

N

% of monotherapy patients

% of all patients in male OAB sub-cohort

% of all male patients

Any OAB drug monotherapy

7946

100.0

64.2

16.3

Any antimuscarinic monotherapy

7443

93.7

60.1

15.3

Solifenacin

2759

34.7

22.3

5.7

Oxybutynin

2613

32.9

21.1

5.4

Tolterodine

1445

18.2

11.7

3.0

Mirabegron

503

6.3

4.1

1.0

Fesoterodine

285

3.6

2.3

0.6

Trospium

227

2.9

1.8

0.5

Flavoxate

49

0.6

0.4

0.1

Darifenacin

47

0.6

0.4

0.1

Propiverine

18

0.2

0.1

0.04

Combination drug therapy

N

% of combination drug therapy patients

% of all patients in male OAB sub-cohort

% of all male patients

Any combination drug therapy

4437

100.0

35.8

9.1

Any BPO drug + any OAB drug

3863

87.1

31.2

7.9

Any BPO drug + any antimuscarinic

3643

82.1

29.4

7.5

Any BPO drug + mirabegron

347

7.8

2.8

0.7

Any alpha-blocker + any OAB drug (± 5-ARI)

3538

79.7

28.6

7.3

Any alpha-blocker + any antimuscarinic (± mirabegron and/or 5-ARI)

3330

75.1

26.9

6.8

Any alpha-blocker + mirabegron (± antimuscarinic and/or 5-ARI)

326

7.3

2.6

0.7

Triple drug therapy (any alpha-blocker + any 5-ARI + any OAB drug)

958

21.6

7.7

2.0

Any OAB drug + any 5-ARI (± alpha-blocker)

1284

28.9

10.4

2.6

Any OAB drug + any 5-ARI (excl. alpha-blocker)

325

7.3

2.6

0.7

Mirabegron + any antimuscarinic (± BPO drug)

307

6.9

2.5

0.6

Any ≥ 2 OAB (± BPO drug)

964

21.7

7.8

2.0

Any ≥ 2 OAB (no BPO drug)

574

12.9

4.6

1.2

Any ≥ 2 antimuscarinics (± BPO drug and/or mirabegron)

666

15.0

5.4

1.4

Solifenacin + tamsulosin

902

20.3

7.3

1.9

Oxybutynin + tamsulosin

364

8.2

2.9

0.7

Tamsulosin + tolterodine

248

5.6

2.0

0.5

Finasteride + solifenacin + tamsulosin

233

5.3

1.9

0.5

Doxazosin + solifenacin

114

2.6

0.9

0.2

Solifenacin + tolterodine

114

2.6

0.9

0.2

Finasteride + oxybutynin + tamsulosin

111

2.5

0.9

0.2

Oxybutynin + solifenacin

102

2.3

0.8

0.2

Finasteride + solifenacin

96

2.2

0.8

0.2

Mirabegron + tamsulosin

96

2.2

0.8

0.2

Doxazosin + oxybutynin

95

2.1

0.8

0.2

Mirabegron + solifenacin

95

2.1

0.8

0.2

Fesoterodine + tamsulosin

83

1.9

0.7

0.2

Dutasteride + solifenacin + tamsulosin

79

1.8

0.6

0.2

Doxazosin + tolterodine

69

1.6

0.6

0.1

Other combinations

1636

36.9

13.2

3.4

Drug class

N

% of all patients in male OAB sub-cohort

% of all male patients

Any OAB drug

12,383

100

25.4

Any OAB drug (no BPO drug)

8520

68.8

17.5

Any antimuscarinic

11,653

94.1

23.9

Total mirabegron

1039

8.4

2.1

Any alpha-blocker

3538

28.6

7.3

Any 5-ARI

1284

10.4

2.6

  1. 5-ARI: 5-alpha reductase inhibitor; BPO: benign prostatic obstruction; LUTS: lower urinary tract symptoms; OAB: overactive bladder
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us